Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.
In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine
Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.
Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.
Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.
Vaccine safety; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Belshe RB, Frey SE, Graham IL, Anderson EL, Jackson LA, Spearman P, Edupuganti S, Mulligan MJ, Rouphael N, Winokur P, Dolor RJ, Woods CW, Walter EB, Chen WH, Turley C, Edwards KM, Creech CB, Hill H, Bellamy AR.Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
JAMA. 2014;312(14):1420-8. doi: 10.1001/jama.2014.12609. PubMed
Bernstein DI, Jackson L, Patel SM, Sahly HM, Spearman P, Rouphael N, Rudge TL Jr, Hill H, Goll JB.Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.
Vaccine. 2014 Sep 16. pii: S0264-410X(14)01240-7. doi: 10.1016/j.vaccine.2014.08.076. [Epub ahead of print]. PubMed
McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson LA, Omer SB, Jacobsen SJ, DeStefano F.The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.
Vaccine. 2014 Aug 6. pii: S0264-410X(14)01025-1. doi: 10.1016/j.vaccine.2014.07.073 [Epub ahead of print]. PubMed
Havers F, Thaker S, Clippard JR, Jackson M, Mclean H, Monto AM, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM.Use of influenza antiviral agents by ambulatory care clinicians during the 2012-13 influenza season.
Clin Infect Dis. 2014 Jul 16. pii: ciu422. [Epub ahead of print].
Washington Post, Sep. 29, 2014